I can't figure out what the preparation is called on this patent I just found on the web. It looks like it was applied for in 2009.
I will copy the whole patent application here... sorry if it is too long.
It even has patient examples of improved tinnitus.
I hope someone can dig up what this product is called.
Oh, I searched under blueberries as I was wondering why my T has been so low for almost a week. I had started taking Salvestrol Platinum and the first extract listed is blueberries. I wanted to know if blueberries has some association with tinnitus. This patent came up.
http://www.freshpatents.com/-dt20090903ptan20090220592.php
Preparation for the treatment of tinnitus
US 20090220592 A1 20090903 US 12282691 20070315 12 DE 10 2006 011 922.3 20060315 20060101 A
A
61 K 36 45 F I 20090903 US B H 20060101 A
A
61 K 9 48 L I 20090903 US B H 20060101 A
A
61 P 27 16 L I 20090903 US B H US 424456 424732 PREPARATION FOR THE TREATMENT OF TINNITUS Stoldt Uwe
München DE
omitted DE LANDO & ANASTASI, LLP
ONE MAIN STREET, SUITE 1100 CAMBRIDGE MA 02142 US
WO PCT/EP2007/002294 00 20070315 20090211
The invention relates to the use of blueberry extract for the preparation of a therapeutic composition for oral administration for the treatment and prevention of tinnitus.
The invention relates to a preparation for oral administration for the treatment of tinnitus which contains blueberry extract as well as antioxidants and micronutrients selected from magnesium oxide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, evening primrose oil and folic acid.
The use of blueberries, as fresh fruit or as (dry) extract for the prevention and treatment of circulatory disorders such as variscose veins, hemorrhoids, diarrhea and a number of ophtalmopathies such as cataract, diabetic retinopathy, glaucoma, macular degeneration and night blindness as well as of excessive strain of the eyes (computer) is widespread.
Tinnitus is a functional disorder of the auditory system which may originate in different levels and structures, without ascertained knowledge as to the pathopsychology of tinnitus being available.
The term "Tinnitus aurium" (Latin: "ear ringing") or short tinnitus relates to a symptom where the afflicted hears sounds which have no exterior source which would be perceptible to other people. In particular if the disorder is chronic, the psychological strain caused by continuous noise in the ear will be substantial. In the course of the disease, many patients develop secondary symptoms such as sleep disorders, concentration disorders, anxiety neuroses and depressions. In many cases, normal life is no longer possible or only to a limited extent. Patient may be faced with occupational or general disability. Due to this strain, many tinnitus patients are suicidal.
The cause is assumed to be a multifactorial event. Since ascertained knowledge as to the pathopsychological basis of tinnitus is not available, a systematic rational medicinal therapy is not possible. In general, the present therapeutic measures are based on multiple approaches and comprise stress management measures, noise masking with special hearing aids and also surgery. However, these therapeutic approaches show no satisfactory results and there is urgent need for an effective preparation for the treatment of tinnitus.
Surprisingly, it was possible to demonstrate in clinical tests that the preparation of the invention, which contains blueberry extract in combination with specific antioxidants and micronutrients, allowed very significant success in the treatment of tinnitus. Tests with volunteers showed that, after a three-month treatment consisting in daily administration of 2×3 capsules, the tinnitus ear noises were significantly reduced or disappeared.
Thus, the present invention provides a new highly effective and purely natural pharmaceutical or dietary preparation which is suitable for the prevention and treatment of tinnitus/acute hearing loss. Contrary to the preparations which are conventionally used, the pharmaceutical preparations of the invention are natural and purely herbal formulations which are also accepted and well tolerated by patients having a negative attitude towards allopathy.
The blueberry extract of the invention is a dry extract from the berries of Vaccinium myrtillus, i.e. of the European blueberry which, according to Anglosaxon usage, is also called "bilberry".
A particularly preferred dry extract of the invention is standardized to at least 25% anthocyanosides.
A typical extract used according to the invention contains up to 4.5% water, up to 5% mineral constituents (sulfuric ashes), up to 5% free anthocyanidines and 25-27.5% glycosidically bound anthocyanidines (anthocyanosides). Such extract is commercially available, e.g. as "Bilberry Purified Dry Extract". The dry extract can be obtained by methods known per se from liquid drug extracts which are prepared by means of percolation, maceration, soxleth method, digestion, particularly, according to pharmacopoeiae instructions (e.g. Bonati A., J. Ethnopharmacol. 1991, April; 32 (1-3): 195-7).
In particular, the blueberry extract used according to the invention can be prepared as briefly described in the following.
Fresh blueberries are pressed to obtain a blueberry juice concentrate which, subsequently, is subjected to ultrafiltration and to ethanol extraction or aqueous alcohol extraction. The extract obtained is concentrated under vacuum to form a paste and dried to form a powder which, then, is ground for obtaining the dry blueberry extract.
An extract of this kind is described in WO 05/092330.
A preferred formulation of the invention contains per dosage unit, such as tablet or capsule:
50 to 500 mg blueberry extract, 10 to 200 mg magnesium (in form of magnesium oxide), 0.2 to 5 mg vitamin B1, 0.2 to 5 mg vitamin B2, 0.2 to 5 mg vitamin B6 and 0.1 to 1 pg vitamin B12.
Further preferred ingredients are folic acid (0.01-10 mg) and evening primrose oil (10-100 mg).
The following formulation is more particularly preferred, in particular, if it is in form of a soft gelatine capsule (amount per dosage unit):
blueberry extract 100-200 mg magnesium (in form of magnesium oxide) 10-20 mg vitamin B1 0.2-1 mg vitamin B2 0.2-1 mg vitamin B6 0.2-1 mg vitamin B12 0.1-1 μg folic acid 0.01-1 mg and evening primrose oil 30-60 mg
The formulation below is most particularly preferred, in particular, in form of a soft gelatine capsule (amount per dosage unit):
blueberry concentrate 150 mg evening primrose oil 50 mg magnesium (in form of magnesium oxide) 18.75 mg folic acid 0.05 mg vitamin B1 0.312 mg vitamin B2 0.625 mg vitamin B6 0.396 mg vitamin B12 0.225 μg
In addition, the dietary or pharmaceutical compositions of the invention may contain pharmaceutical adjuvants such as fillers (carriers), e.g. soy bean oil or partially hydrogenated soybean oil, beeswax, butterfat and lecithin for soft gelatine capsules, disintegrants, binding agents, flow regulation agents, lubricants, emulsifiers, solvents or sorbents.
The dietary or pharmaceutical compositions of the invention can be formulated in any dosage form that is suitable for oral administration according to the standard methods used in the technical field, with solid dosage forms for oral administration such as tablets, hard gelatine capsules and soft gelatine capsules being preferred. Soft gelatine capsules are most particularly preferred. According to the invention, soft gelatine capsules are preferably oval soft gelatine capsules with a size of 2 to 20 minim. and oblong soft gelatine capsules with a size of 6 to 22 minim., most preferably oval soft gelatine capsules with a size of 10 minim.
In this context, it is also preferred that the dosage form is present in specific primary packages such as press-through packages or blister packs, i.e. that it is blistered.
The results described below clearly show that the composition of the invention, which contains blueberry extract in combination with specific antioxidants and micronutrients, allows to achieve very significant therapeutic success in the treatment of tinnitus.
next........
I will copy the whole patent application here... sorry if it is too long.
It even has patient examples of improved tinnitus.
I hope someone can dig up what this product is called.
Oh, I searched under blueberries as I was wondering why my T has been so low for almost a week. I had started taking Salvestrol Platinum and the first extract listed is blueberries. I wanted to know if blueberries has some association with tinnitus. This patent came up.
http://www.freshpatents.com/-dt20090903ptan20090220592.php
Preparation for the treatment of tinnitus
US 20090220592 A1 20090903 US 12282691 20070315 12 DE 10 2006 011 922.3 20060315 20060101 A
A
61 K 36 45 F I 20090903 US B H 20060101 A
A
61 K 9 48 L I 20090903 US B H 20060101 A
A
61 P 27 16 L I 20090903 US B H US 424456 424732 PREPARATION FOR THE TREATMENT OF TINNITUS Stoldt Uwe
München DE
omitted DE LANDO & ANASTASI, LLP
ONE MAIN STREET, SUITE 1100 CAMBRIDGE MA 02142 US
WO PCT/EP2007/002294 00 20070315 20090211
The invention relates to the use of blueberry extract for the preparation of a therapeutic composition for oral administration for the treatment and prevention of tinnitus.
The invention relates to a preparation for oral administration for the treatment of tinnitus which contains blueberry extract as well as antioxidants and micronutrients selected from magnesium oxide, vitamin B1, vitamin B2, vitamin B6, vitamin B12, evening primrose oil and folic acid.
The use of blueberries, as fresh fruit or as (dry) extract for the prevention and treatment of circulatory disorders such as variscose veins, hemorrhoids, diarrhea and a number of ophtalmopathies such as cataract, diabetic retinopathy, glaucoma, macular degeneration and night blindness as well as of excessive strain of the eyes (computer) is widespread.
Tinnitus is a functional disorder of the auditory system which may originate in different levels and structures, without ascertained knowledge as to the pathopsychology of tinnitus being available.
The term "Tinnitus aurium" (Latin: "ear ringing") or short tinnitus relates to a symptom where the afflicted hears sounds which have no exterior source which would be perceptible to other people. In particular if the disorder is chronic, the psychological strain caused by continuous noise in the ear will be substantial. In the course of the disease, many patients develop secondary symptoms such as sleep disorders, concentration disorders, anxiety neuroses and depressions. In many cases, normal life is no longer possible or only to a limited extent. Patient may be faced with occupational or general disability. Due to this strain, many tinnitus patients are suicidal.
The cause is assumed to be a multifactorial event. Since ascertained knowledge as to the pathopsychological basis of tinnitus is not available, a systematic rational medicinal therapy is not possible. In general, the present therapeutic measures are based on multiple approaches and comprise stress management measures, noise masking with special hearing aids and also surgery. However, these therapeutic approaches show no satisfactory results and there is urgent need for an effective preparation for the treatment of tinnitus.
Surprisingly, it was possible to demonstrate in clinical tests that the preparation of the invention, which contains blueberry extract in combination with specific antioxidants and micronutrients, allowed very significant success in the treatment of tinnitus. Tests with volunteers showed that, after a three-month treatment consisting in daily administration of 2×3 capsules, the tinnitus ear noises were significantly reduced or disappeared.
Thus, the present invention provides a new highly effective and purely natural pharmaceutical or dietary preparation which is suitable for the prevention and treatment of tinnitus/acute hearing loss. Contrary to the preparations which are conventionally used, the pharmaceutical preparations of the invention are natural and purely herbal formulations which are also accepted and well tolerated by patients having a negative attitude towards allopathy.
The blueberry extract of the invention is a dry extract from the berries of Vaccinium myrtillus, i.e. of the European blueberry which, according to Anglosaxon usage, is also called "bilberry".
A particularly preferred dry extract of the invention is standardized to at least 25% anthocyanosides.
A typical extract used according to the invention contains up to 4.5% water, up to 5% mineral constituents (sulfuric ashes), up to 5% free anthocyanidines and 25-27.5% glycosidically bound anthocyanidines (anthocyanosides). Such extract is commercially available, e.g. as "Bilberry Purified Dry Extract". The dry extract can be obtained by methods known per se from liquid drug extracts which are prepared by means of percolation, maceration, soxleth method, digestion, particularly, according to pharmacopoeiae instructions (e.g. Bonati A., J. Ethnopharmacol. 1991, April; 32 (1-3): 195-7).
In particular, the blueberry extract used according to the invention can be prepared as briefly described in the following.
Fresh blueberries are pressed to obtain a blueberry juice concentrate which, subsequently, is subjected to ultrafiltration and to ethanol extraction or aqueous alcohol extraction. The extract obtained is concentrated under vacuum to form a paste and dried to form a powder which, then, is ground for obtaining the dry blueberry extract.
An extract of this kind is described in WO 05/092330.
A preferred formulation of the invention contains per dosage unit, such as tablet or capsule:
50 to 500 mg blueberry extract, 10 to 200 mg magnesium (in form of magnesium oxide), 0.2 to 5 mg vitamin B1, 0.2 to 5 mg vitamin B2, 0.2 to 5 mg vitamin B6 and 0.1 to 1 pg vitamin B12.
Further preferred ingredients are folic acid (0.01-10 mg) and evening primrose oil (10-100 mg).
The following formulation is more particularly preferred, in particular, if it is in form of a soft gelatine capsule (amount per dosage unit):
blueberry extract 100-200 mg magnesium (in form of magnesium oxide) 10-20 mg vitamin B1 0.2-1 mg vitamin B2 0.2-1 mg vitamin B6 0.2-1 mg vitamin B12 0.1-1 μg folic acid 0.01-1 mg and evening primrose oil 30-60 mg
The formulation below is most particularly preferred, in particular, in form of a soft gelatine capsule (amount per dosage unit):
blueberry concentrate 150 mg evening primrose oil 50 mg magnesium (in form of magnesium oxide) 18.75 mg folic acid 0.05 mg vitamin B1 0.312 mg vitamin B2 0.625 mg vitamin B6 0.396 mg vitamin B12 0.225 μg
In addition, the dietary or pharmaceutical compositions of the invention may contain pharmaceutical adjuvants such as fillers (carriers), e.g. soy bean oil or partially hydrogenated soybean oil, beeswax, butterfat and lecithin for soft gelatine capsules, disintegrants, binding agents, flow regulation agents, lubricants, emulsifiers, solvents or sorbents.
The dietary or pharmaceutical compositions of the invention can be formulated in any dosage form that is suitable for oral administration according to the standard methods used in the technical field, with solid dosage forms for oral administration such as tablets, hard gelatine capsules and soft gelatine capsules being preferred. Soft gelatine capsules are most particularly preferred. According to the invention, soft gelatine capsules are preferably oval soft gelatine capsules with a size of 2 to 20 minim. and oblong soft gelatine capsules with a size of 6 to 22 minim., most preferably oval soft gelatine capsules with a size of 10 minim.
In this context, it is also preferred that the dosage form is present in specific primary packages such as press-through packages or blister packs, i.e. that it is blistered.
The results described below clearly show that the composition of the invention, which contains blueberry extract in combination with specific antioxidants and micronutrients, allows to achieve very significant therapeutic success in the treatment of tinnitus.
next........